I understand and GL on your investments. If I had to pick one stock with PCYC type upside (ie 200 -300 bagger) this would be it. Its a matter of a few binary events, each of which could kill the company or allow it to prosper until the next event. The next event is next year.
Given its value, right now the market is only assigning a 4% probability of ultimate success.
thanks for info. they filed but may not be done. this is first major ( 1 M shares) ownership by a fund
strike price set by recent price per share. i wonder if downdraft was engineered for this and now that options are granted we turn up.
You are shooting yourself in the foot with sales of stock to lower the cost of the warrants. The only winners are the broker commissions and the shorts. As soon as you stop this insanity the stock should go up. But I continue to thank you and all the bears on this thread for the continued gifts.
Your comments are outstanding. It may explain the improved safety associated with the EU patients.
Porcine model results published Jan 2014, indicate 99% efficiency for new filter. Is it being used in P2 trials?
Long term - between 0 (drug failure) and $200 (drug works for MS and has other indications)
Short term - being taken down - either shorts, panic longs or smart money accumulation (underwriter?) perhaps in advance of analyst coverage? all imo.
Warma - overpaid by about 50% compared to similar companies. Plus - deal with Merck Serono (could ultimately be game changer), Negative - discounted financing. Seaman has clout to oust Warma if he is inclined but he hasn't. Seaman has also bought another 0.5M units (shares and warrants)
Thanks for the healthy, well deserved skepticism. If I may ask, what is your interest in posting here? Re. news in next few weeks - not necessarily clinical news, but news about insider buying, possible coverage etc. The market for small caps is inefficient. Eg - Anth hovered in the 1's for a fews weeks after announcing partnership, then newsletter picked up on it and it tripled in short period of time on heavy volume.
Re long term - if Merck Serono exercises option, then P3 will be cash flow positive. Eg PCYC went from $1 to $10 to $100 before FDA approval. Bob Duggan turned $10M investment into $1B during this timeframe (now over $2B). The money I have at risk will not impact my lifestyle if I lose it all, but has the potential to increase to eight figures if things go well. This is a very asymettric situation - yes the ability to lose it all, but also the ability to see market cap increase into the billions.
Cowen, a co-underwriter of SNTA's recent offering initiated coverage of SNTA. Management should push Roth to initiate coverage of DCTH or take their future business elsewhere
Why do you think Seaman doubled his investment in company? Agree that its been painful for long term shareholders and skepticism is warranted. But if drug works its market cap becomes multi billion $.
The use of term "next up" implies no news between now and june. I'd say the probability of that is less than 1%. Next up literally will be the indentification of insider buying by insider websites.
i suspect underwriter clients are selling shares so that they are left with warrants at very low cost. Of course they would like 55 c pps so that warrant would essential be free.